-+ 0.00%
-+ 0.00%
-+ 0.00%

INNATE PHARMA HIGHLIGHTS DURABLE RESPONSES TO LACUTAMAB IN SEZARY SYNDROME AND MYCOSIS FUNGOIDES

Reuters·05/23/2025 05:00:00

Please log in to view news